ImmunityBio (IBRX) Non Operating Investment Income (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Non Operating Investment Income data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Non Operating Investment Income rose 160.88% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 35.9% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, down 19.69% from the prior year.
• Non Operating Investment Income for Q1 2026 stood at $2.3 million, up from $2.3 million in the prior quarter.
• Over the last five years, Non Operating Investment Income for IBRX reached as high as $3.1 million in Q1 2024 and fell as low as -$3.8 million in Q4 2022.
• Historically, Non Operating Investment Income has averaged $866764.7 across 5 years, with a median of $1.2 million in 2025.
• Across the five-year window, Non Operating Investment Income sank 916.95% in 2022 and surged 5037.14% in 2024, its largest moves.
• Year by year, Non Operating Investment Income stood at -$3.8 million in 2022, then soared by 112.69% to $484000.0 in 2023, then jumped by 145.25% to $1.2 million in 2024, then soared by 93.6% to $2.3 million in 2025, then rose by 0.7% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.